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other groups, namely sulfonylureas and thiazolidinediones, it has been declining 
each year on average by 2 % and 15 %, respectively. ConClusions: The uptake of 
incretin-based drugs since 2008 has been rapid and their utilization keeps rising, 
apparently at the expense of other drugs, namely older sulfonylurea derivatives and 
thiazolidinediones. Consequently the overall public expenditure on anti-diabetic 
therapy has been increasing.
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objeCtives: This study describes the extent of non-adherence (NA) and non-per-
sistence (NP) with Glucagon-like peptide 1 agonists (GLP-1) and oral anti-diabetic 
(OAD) therapy in T2DM patients in clinical practice in Germany. Methods: Claims 
data from a German sickness fund (AOK Plus) from 2010-2012 were used to identify 
patients with ≥ 1 diagnosis for T2DM. NA/NP were measured for patients initi-
ating new T2DM medication (no prescription of respective medication in prior 6 
months) over a minimum of 12 months. A 100% adherence to therapy was assumed 
equivalent to the drug-specific DDD (defined daily dosage). NP was defined as a 
medication gap ≥ 90 days. Adherence was calculated via medication possession 
ratios (MPR), NA was defined as MPR< 80%. Descriptive analyses with percentage 
of patients affected by NP and/or NA were conducted. Results: The NP analysis, 
included 2,490/42,891 T2DM patients initiating GLP-1s/OADs. Among GLP-1 patients, 
408/1,727/135 received twice-daily (BID; exenatide)/once-daily (OD; liraglutide)/once-
weekly (OW; exenatide) therapies. Average age for GLP-1/OAD users was 56 (SD 
10.8) /67 (SD 12.6) years. After 12 months, the percentage of patients with NP was 
36.83% (all GLP-1s), 42.65% (BID), 37.64% (OD), 27.41% (OW), and 55.87% (OAD). The 
NA analysis included 2,154/34,128 T2DM patients initiating GLP-1/OAD therapy with 
≥ 1 follow-up prescription. Average age was 56 (SD 10.6) /66 (SD 12.2) years. Average 
MPR was 88.2% (all GLP-1s), 87.8% (BID), 88.2% (OD), 95.0% (OW), and 63.2% (OAD). 
Percentage of patients affected by NA was 21.96% (all GLP-1s), 23.98% (BID), 22.00% 
(OD), 5.74% (OW), and 65.82% (OAD). ConClusions: In this German dataset, overall 
patients with T2DM had low rates of adherence and persistence despite the chronic 
nature of the disease and clinical sequelae. Higher adherence and persistence rates 
were observed with GLP-1s than with OAD medications and also with less frequently 
dosed GLP-1s.
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objeCtives: To describe the sequential treatment classes of type 2 diabetes (T2DM) 
patients initiating antidiabetic drug therapy in the Netherlands, UK (UK), Spain, 
Italy and France. To describe treatment scaling (intensification or de-intensification) 
in the overall T2DM population. Methods: Antidiabetic drug use during a 5-year 
study period (2007-2011/2008-2012) (n= 639,088) was obtained from electronic health 
care databases. A standardized analytic tool performed treatment pattern analyses 
in each database for the overall population and those initiating treatment. Oral 
monotherapy was defined as first line, oral dual therapy as second line, multiple oral 
treatments or oral in combination with an injectable as third line and injectables 
only as fourth line therapy. Results: Newly treated patients represented 33-42% 
of the overall T2DM population. Metformin monotherapy was the most common 
initial therapy (65%-87%). Around 35% (Netherlands, Italy, UK) to 45% (Spain, France) 
switched treatment within the study period. The first switch was most often to met-
formin plus a sulfonylurea (SU) in the Netherlands (47%), UK (45%), Spain (22%), Italy 
(17%), but to DPP4 inhibitors in France (15%). DPP4 inhibitor use increased during 
the study period (France 0% to 27%, UK and Spain < 1% to 9%) but remained limited 
in the Netherlands (4%) and Italy (2%). In the total cohort, first line treatment was 
most prevalent over all the years in all countries (around 50%). Intensification was 
the most common switch. Switching patients mostly stepped up or down one line 
at a time, but larger steps were also observed. Fourth line therapy was uncommon 
in France (1-2%) but accounted for about 10% in the other countries. ConClusions: 
SU remained the most common add-on treatment to metformin in most European 
countries while DPP4 inhibitor use was common in France and increased in other 
countries. Most T2DM patients are treated with oral monotherapy.
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objeCtives: Recent studies reported that seeing an endocrinologist is associated 
with better compliance with guidelines on diabetes management. This study aims 
at investigating the socioeconomic determinants of endocrinologist visits among a 
French population of diabetics. Methods: We used claim data collected for 66,508 
affiliates of a French social security provider (MGEN). Patients were aged over 18 
and treated for diabetes (types I and II). We ran logistic regressions to explore which 
factors were associated with the probability of consulting an endocrinologist. We 
controlled for patients’ socioeconomic characteristics (sex, age, income, marital 
status, activity status), type of treatment, medical care and health status. We also 
controlled for macro-level variables, such as the cost for a visit, the distance to the 
office and the medical density. Results: Women, married patients, and those work-
ing are more likely to consult an endocrinologist (p< 0.001). Age has a non-linear 
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objeCtives: Investigate how official drug safety warnings for thiazolidinediones 
(TZDs, rosiglitazone and pioglitazone) affected prescription trends for TZDs in 
Denmark and Germany and to compare the prescription patterns to data published 
for Australia, UK and the US. Methods: Identified the timing and content of all 
drug warnings for TZDs using the FDA’s and EMA’s databases. Using pharmaceutical 
claims data on all diabetes patients in Denmark and a large public health insurance 
fund in Germany, plotted the number of defined daily dosages (DDDs) per month for 
rosiglitazone and pioglitazone normalized per 1000 insurees for both countries from 
January 2007 -December 2013. Results: In Denmark rosiglitazone monotherapy 
prescriptions remained almost constant after publication of the safety warnings 
in May 2007 until drug suspension in September 2010, but declined fairly fast in 
Germany. Prescription of rosiglitazone combined with metformin declined by 1/3 
compared to their May 2007 levels in both countries. Overall market penetration of 
rosiglitazone prior to the drug warnings was ~1 DDD per day per 1000 insurees in 
Germany and 0.36 in Denmark, and therefore much lower than in Australia where 
rosiglitazone peaked at about 2 DDDs per 1000 insurees. The FDA’s safety warning 
for increased risk of heart failure for all TZDs in August 2007 did not affect pre-
scription growth rates for pioglitazone in Germany or Denmark. However, pioglita-
zone prescriptions declined after the FDA’s and EMA’s safety warning for possibly 
increased risk of bladder cancer for pioglitazone patients in June and July 2011 in 
both countries. ConClusions: TZD prescriptions in Germany and Denmark did not 
decline as radically after the publication of safety warnings as in other countries. 
Differences in reaction speed may reflect different levels of market penetration prior 
to the drug safety warnings and differences in the intensity of the safety warning 
issued by the drug administration authority.
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objeCtives: Type 2 Diabetes is on the rise in many Asian countries with growing 
economic prosperity. Treatment patterns of diabetic patients in South East Asia have 
rarely been studied using administrative data. Our objective was to understand med-
ication use patterns among Malaysian patients with diabetes with comorbidities in 
the primary health care setting. This may be useful for understanding treatment 
strategies in subgroups of patients with diabetes who tend to pose more complex 
challenges in clinical decision-making. Methods: Data was obtained from diabetic 
patients who were audited in the NDR in 2012. Descriptive analysis was used to 
describe medication usage for patients with various comorbidities. Medications of 
interest were antiplatelet medications, lipid-lowering agents, anti-hypertensive and 
various classes of anti-diabetic medications including insulin. Results: A total of 
130,270 patients were identified with comorbidities. Mean age of patients was 59.8 
years old and 60.2% were female. A majority of patients were hypertensive (70.3%), 
more than half were dyslipidemic (55.1%). Other comorbidities such as retinopathy, 
ischemic heart disease (IHD), cerebrovascular disease, nephropathy, diabetic foot 
ulcer, amputation, hypertension and dyslipidemia were recorded among less than 
10% of patients. Among non-diabetes medications, statins was the most commonly 
used ranging from 64.6% to 86.3% for various comorbidities. This was followed by 
ACE-inhibitors and aspirin. Among anti-diabetic medications, metformin was the 
most commonly prescribed followed by sulfonylureas and insulins. ConClusions: 
The registry data was able to shed light on patterns of medication usage among 
diabetic patients with comorbidities. Perhaps in the future, this data can be used 
to evaluate long-term outcomes among patients on various treatment plans and 
finally to inform more evidence-based clinical management strategies relating to 
medication use.
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objeCtives: The objective was to analyze evolving consumption, public costs as 
well as prescription practice pattern of the newer anti-diabetic drugs interfering 
with incretin system, i. e. DPP-IV inhibitors (“gliptins”) and GLP-1 mimetics, and 
compare it to other drugs in the anti-diabetic portfolio. Methods: The phar-
macy claims-based database of the General Health Insurance Company of the 
Czech Republic (VZP CR) was used as the data source. An insured person with a 
recorded prescription for any of the drugs of interest (ATC3 classification A10B: 
blood glucose-lowering drugs excl. insulins) between 2008 and 2013 was defined as 
a patient. Information on pricing and reimbursement were obtained from the files 
of administrative proceedings at the State Institute for Drug Control. Results: 
Since the introduction of sitagliptin in autumn 2008 its utilization rose to 2.1 DDD/
TID in 2013, which makes it the most prescribed incretin-based drug. Overall con-
sumption of all incretin-based therapies was 5.4 DDD/TID in 2013 and the patient 
number represents 9 % of all patients taking any anti-diabetic drug of the ATC A10B 
group (except for insulins). However, in terms of public costs incretin-based agents 
represent already 55% of all the blood glucose-lowering therapy of the evaluated 
A10B group (insulines excluded). In comparison, the utilization of the 1st line drug 
metformin between 2008 and 2013 has been annually rising by 5 % to 10 %, while in 
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objeCtives: The relationship between resource utilisation and patient phenotype 
in type 2 diabetes (T2D) is not well characterised. This study aimed to assess fac-
tors associated with weight gain (WG) and the occurrence of hypoglycaemia in 
T2D patients managed with metformin plus sulfonylurea (M+S) and any associated 
impact upon hospital resource utilisation. Methods: The study was a retrospec-
tive cohort study using the UK Clinical Practice Research Datalink (CPRD) and the 
Hospital Episode Statistics (HES) database. The association between phenotypic 
factors at baseline (therapy escalation from metformin to M+S) with WG (> 2kg 
weight change over 12 months) and presence of any recorded hypoglycaemia over 
12 months following therapy escalation was assessed using logistic regression. 
Hospitalisation associated with increasing body mass index (BMI) and hypoglycae-
mia was also assessed. Results: A total of 11,071 patients met the study inclusion/
exclusion criteria. WG was observed in 28.35% of patients and was significantly 
associated with baseline age (OR= 0.99), female gender (OR= 0.87), baseline weight 
(OR= 1.003) and HbA1c (OR= 1.06). Hypoglycaemia occurred in 1.3% of patients and 
was significantly associated with duration of diabetes (OR= 1.04), baseline HbA1c 
(OR= 0.86) and prior complications status (OR= 1.92). Hospitalisation occurred in 10% 
of patients and was significantly associated with BMI (OR= 1.02) but not hypoglycae-
mia. The mean number of hospital admissions over the follow-up period was 1.7, 1.8, 
1.9 and 3.1 in those with BMIs at the time of admission in the normal, overweight, 
obese and morbidly obese categories respectively. ConClusions: This real-world 
observational analysis suggests there are identifiable phenotypic characteristics 
predictive of WG and hypoglycaemia. This study also shows a general relationship 
between increasing BMI and hospitalisation that may not be adequately captured 
in widely used vascular risk equations such as UKPDS in which BMI has minimal 
influence on risk. Consequently, the value of diabetes management strategies that 
minimise WG may be underestimated.
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objeCtives: Frequency of self-monitoring of blood glucose (SMBG) varies in 
patients with type 2 diabetes mellitus (T2DM) and there is debate as to the true 
benefit it plays in the management of the condition. The aim of this study was to 
compare the frequency of SMBG using patient medication record (PMR) dispensed 
data, with self-reported data, and to assess the relationship between type of glu-
cose-lowering therapy to SMBG frequency among patients with T2DM dispensed 
glucose test strips. Methods: Patients with T2DM were identified in community-
pharmacies (n= 116) using PMRs in 2012. Patients who consented to participation 
were surveyed in a face-to-face interview where self-reported (SR) frequency 
of SMBG was determined. Dispensed data were classified by the mechanism of 
action of the blood glucose lowering regimen, (secretagogues vs. sensitisers). Test 
strip use over a 12 month period was calculated and compared to SR use from 
the patient survey. Analysis was performed in MS Excel® and SAS®. Results: 
Data from 484 patients were analysed (mean age 65yrs). Sensitising agents alone 
accounted for 45% of the cohort, secretagogues alone - 8%, a combination of both 
- 42%, and diet 5%. Approximately 52% of patients reported frequency of SMBG as 
once or twice daily vs 56% in the dispensed data. 13% of patients reported a fre-
quency of at least 3 times daily vs 21% for PMR data. There was no statistically sig-
nificant difference in SR frequency among those on the various glucose-lowering 
regimens. No correlations were found between frequency of use and age, gender, 
place of residence or number of prescribed medicines. ConClusions: Results 
from this study highlight (i) differences in frequency of blood glucose monitoring 
between dispensed data and SR data and (ii) the difficulty in accurately capturing 
this type of data. A reliance on either type of data alone may be insufficient to 
accurately inform decision making.
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objeCtives: Hypoglycaemia is common in diabetic patients, often as a side effect 
of a treatment. Its occurrence can influence patients’ professional life and gener-
ate extra direct costs to the health care system. Severe (requiring another person’s 
assistance) hypoglycaemic events (SHEs), especially leading to hospitalisation, are 
associated with the highest burden and for that reason their real frequency and 
costs should be calculated properly. The aim of the study was to assess the accuracy 
of reporting of hypoglycaemia to the National Health Fund in Poland. Methods: 
A combination of prospective and retrospective designs was applied. A detailed 
retrospective analysis of 117 hospitalised patients’ case histories was performed 
from the period of February-March 2013. In addition, prospectively, in March and 
April 2013, 45 patients were interviewed and their clinical records were analysed. 
Information was collected in special case report forms. Real hospitalisation costs 
were also calculated. Results: In the retrospective arm hypoglycaemia affected 42 
patients (55% of type 1 and 25% of type 2) and 85 SHEs were recorded. Only 2 patients 
were reported in the hypoglycaemia DRG group compared to a broader diabetes/
hyperglycaemia DRG group, where the financing level is higher. A financial differ-
ence equal to 7,082 EUR was generated due to more favourable classification of these 
cases. In the prospective arm 20 patients experienced hypoglycaemia, whereas only 
one was coded as hypoglycaemic. It has generated 2,247 EUR difference. Even with 
this financially more favourable, (still clinically justified but less precise) coding 
hypoglycaemic patients generated losses equal to 23,628 EUR in retrospective and 
5,053 EUR in prospective group. ConClusions: Our study provided a direct proof 
association with the probability of seeing an endocrinologist: rates of specialist 
visits are the largest under the age of 25 (p< 0.05). In addition, people treated with 
insulin and those with another endocrine disorder are more likely to see a special-
ist (p< 0.001). In contrast, the newly diagnosed and patients followed by a general 
practitioner (GP) present lower probabilities of specialist visits (p< 0.001). Moreover, 
the probability of specialist visit rises when the density of endocrinologists is large 
in the patients’ neighbourhood, while it decreases with the distance (in kilome-
tres) from the patients’ house to the endocrinologist’s office. Finally, the chances 
of seeing a specialist increase with income and decrease as the cost for a visit 
rises. ConClusions: Our results are consistent with previous literature showing 
evidence of the existence of a substitution effect between GPs and specialists in 
diabetes care. We show that financial barriers exist even in a population of patients 
receiving national health insurance coverage.
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objeCtives: Severe hypoglycemic events (SHE) contribute to health care utiliza-
tion for insulin-dependent diabetics, and may drive expenditures by health care 
payers. Rescue treatment for SHE includes glucagon kits, which are administered 
by caregivers and difficult to use. Consequently, there are high rates of unsuccess-
ful administration, leading to increased health care service use. A new kit under 
development aims to ease the burden of administration by reducing the complex-
ity. The new device aims to increase successful use and lower rates of health care 
service utilization. This study aimed to understand payers’ receptivity to this value 
proposition. Methods: Seven medical directors from US payers were interviewed, 
representing commercial, Medicare, Medicaid and other covered lives. The interview 
was designed to understand plans’ focus on diabetes and hypoglycemia, cover-
age/reimbursement of current kits, and impressions of characteristics of the new 
kit. Results: The prevention of SHE is not a concern for insurers; the risk of SHE 
is largely a type 1 problem, representing a small subset of their overall diabetic 
population. While payers are confident in current kits’ effectiveness, they are not 
focused on managing access to such a low-volume treatment. Current kits are cov-
ered by insurers without restrictions, and contracting is not prevalent due to low 
volume. Payers believe the new kit will be an improvement over current kits, but do 
not believe it will reduce the cost of SHE. ConClusions: Payers feel that the new 
kit will be an improvement over currently available kits, but are skeptical that the 
ease of use will translate into lower health care service use. Additionally, SHE is not 
a major cost driver among their diabetic population; therefore, SHE is not a high-
priority condition. Consequently, for optimal market access and reimbursement, the 
new kit must demonstrate significant reductions in high-cost health care utilization 
(e.g., ED, hospitalizations) to justify a premium price without coverage restrictions.
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objeCtives: The primary objective was to assess the impact of using ‘metformin 
plus sulphonylureas’ (Met+SU) in comparison with ‘metformin plus other oral 
anti-hyperglycaemic agents’ (Met+OHA) in patients with Type 2 Diabetes (T2D) 
on diabetes-associated secondary health care utilisation in the UK. The second-
ary objectives included investigating individual components of the primary objec-
tive. Methods: This retrospective cohort study used data from the Clinical Practice 
Research Datalink (CPRD) linked to Hospital Episodes Statistics. Adults (≥ 40 years) 
with T2D initiated on dual therapy with Met+SU or Met+OHA following metformin 
monotherapy were identified during the period April 2003–March 2012 and com-
prised the two study cohorts. Propensity scores were estimated and Met+SU patients 
caliper matched to Met+OHA patients to balance the covariates (including HbA1C 
and duration of diabetes at baseline). Diabetes-associated secondary health care 
utilisation (inpatient admissions and outpatient visits) were measured from > 6 
months post-initiation of dual therapy until treatment change or end of follow-up. 
Outcomes were calculated as rate ratios (RR), adjusted for over dispersion using 
negative binomial regression and propensity score for covariates. Results: 14,416 
patients in total were identified and in the directly matched analysis, 1,704 patients 
were included in each cohort. For the primary objective, the Met+SU cohort had a 
numerically higher rate of diabetes-related secondary health care utilisation than 
Met+OHAs (adjusted RR 1.12, 95% confidence interval [95%CI]: 0.97-1.29). For the 
secondary endpoints examining individual components, the adjusted RR for Met+SU 
cohort for inpatient admissions was 1.34 (95%CI 0.92–1.96) and 1.10 (95%CI 0.95-1.28) 
for outpatient visits. Macrovascular complications, accounting for 68.7% of inpa-
tient admissions, occurred at a significantly higher rate in the Met+SU cohort than 
Met+OHA (adjusted RR 1.77, 95%CI: 1.15-2.71). ConClusions: Glucose-lowering 
combination therapy with metformin plus sulphonylurea is associated with a direc-
tionally higher rate of secondary health care utilisation than metformin plus other 
oral anti-hyperglycaemic agents.
PDB161
fActors AssociAteD With WeiGht GAiN AND hyPoGlycAeMiA AND the 
iMPAct uPoN hosPitAlisAtioN iN tyPe 2 DiABetes PAtieNts MANAGeD 
With MetforMiN Plus sulPhoNylureA
McEwan P.1, Gordon J.1, Evans M.2, Puelles J.3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2University Hospital Llandough, 
Cardiff, UK, 3Takeda UK Ltd, London, UK
